Literature DB >> 15934305

Celecoxib inhibits proliferation and induces apoptosis via cyclooxygenase-2 pathway in human pancreatic carcinoma cells.

Gaosong Wu1, Jilin Yi, Fang Di, Shengquan Zou, Xingrui Li.   

Abstract

In order to evaluate the effects and mechanisms of celecoxib in inhibiting proliferation and inducing apoptosis on human pancreatic carcinoma cells, the anti-proliferative effect was measured by using methabenzthiazuron (MTT) assay. Cell cycle and apoptosis were analyzed by using flow cytometry (FCM), and the PGE2 levels in the supernatant of cultured pancreatic carcinoma cells were quantitated by enzyme-linked immunoabsordent assay (ELISA). Our results showed that celecoxib suppressed the production of PGE2 and inhibited the growth of JF-305 cells, and the anti-proliferative effect of celecoxib could be abolished by addition of PGE2. FCM revealed that celecoxib could inhibit proliferation and induce apoptosis by Gl- S cell cycle arrest. It was concluded that cyclooxygenase-2 specific inhibitor celecoxib could inhibit proliferation and induced apoptosis of human pancreatic carcinoma cells via suppression of PGE2 production in vitro.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15934305     DOI: 10.1007/BF02831383

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  9 in total

1.  Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors.

Authors:  M Richter; M Weiss; I Weinberger; G Fürstenberger; B Marian
Journal:  Carcinogenesis       Date:  2001-01       Impact factor: 4.944

2.  Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.

Authors:  Yoshimi Kakiuchi; Shingo Tsuji; Masahiko Tsujii; Hiroaki Murata; Naoki Kawai; Masakazu Yasumaru; Arata Kimura; Masato Komori; Takanobu Irie; Eiji Miyoshi; Yutaka Sasaki; Norio Hayashi; Sunao Kawano; Masatsugu Hori
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

3.  Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.

Authors:  R F Jacoby; C E Cole; K Tutsch; M A Newton; G Kelloff; E T Hawk; R A Lubet
Journal:  Cancer Res       Date:  2000-04-01       Impact factor: 12.701

4.  Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2.

Authors:  M Tsujii; R N DuBois
Journal:  Cell       Date:  1995-11-03       Impact factor: 41.582

5.  Expression of cyclooxygenase 2 and cytosolic phospholipase A(2) in the liver tissue of patients with chronic hepatitis and liver cirrhosis.

Authors:  Jidong Cheng; Hiroyasu Imanishi; Hiroko Iijima; Soji Shimomura; Tetsuya Yamamoto; Yoshiki Amuro; Akira Kubota; Toshikazu Hada
Journal:  Hepatol Res       Date:  2002-07       Impact factor: 4.288

Review 6.  The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention.

Authors:  F M Giardiello; G J Offerhaus; R N DuBois
Journal:  Eur J Cancer       Date:  1995 Jul-Aug       Impact factor: 9.162

7.  Expression of cyclooxygenase-1 and -2 in extra-hepatic cholangiocarcinoma.

Authors:  Gao-Song Wu; Ju-Hua Wang; Zheng-Ren Liu; Sheng-Quan Zou
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2002-08

8.  Sulindac inhibits colorectal tumour growth, but not prostaglandin synthesis in the rat.

Authors:  D Charalambous; S A Skinner; P E O'Brien
Journal:  J Gastroenterol Hepatol       Date:  1998-12       Impact factor: 4.029

9.  Association between cyclo-oxygenase-2 overexpression and missense p53 mutations in gastric cancer.

Authors:  W K Leung; K F To; Y P Ng; T L Lee; J Y Lau; F K Chan; E K Ng; S C Chung; J J Sung
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

  9 in total
  1 in total

1.  Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe.

Authors:  S M Sureban; S Ramalingam; G Natarajan; R May; D Subramaniam; K S Bishnupuri; A R Morrison; B K Dieckgraefe; D J Brackett; R G Postier; C W Houchen; S Anant
Journal:  Oncogene       Date:  2008-04-21       Impact factor: 9.867

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.